Bisphosphonate approved, but not being launched. (Convenient Dosing Sought).
Publication: OB GYN News
Publication Date: 01-JUL-03
Author: Mechcatie, Elizabeth
How to access the full article: Free access to all articles is available courtesy of your local library. To access the full article click the "See the full article" button below. You will need your US library barcode or password.
The Food and Drug Administration has approved a daily formulation of ibandronate sodium for the treatment and prevention of postmenopausal osteoporosis, but the manufacturer has no immediate plans to launch the bisphosphonate until more convenient dosing regimens are approved.
The trade name of the drug, approved in a tablet...
Read the full article for free courtesy of your local library.
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
